Multidrug resistance in breast cancer: A meta-analysis of MDR1/gp170 expression and its possible functional significance

Journal of the National Cancer Institute

Volumn 89, Issue 13, 1997, Pages 917-931

  Trock, Bruce J ^a   Leonessa, Fabio ^a   Clarke, Robert ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL TRIAL; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; META ANALYSIS; MULTIDRUG RESISTANCE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; STATISTICAL ANALYSIS;

EID: 0030920342     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.13.917     Document Type: Article

References (121)

1. Henderson IC, Shapiro CI. Adjuvant chemotherapy: an overview. In: Powles T, Smith IE, editors. Medical management of breast cancer. London: Dunitz, 1991:197-215.
2. Harris JR, Morrow M, Bonadonna G. Cancer of the breast. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: Lippincott, 1993:1264-332.
3. Clarke R, Dickson RB. The interactions among steroid hormones, antiestrogens, biological response modifiers and cytotoxic drugs in breast cancer. In: Tsuruo T, Ogawa M, Carter SK, editors. Drug resistance as a biochemical target in cancer chemotherapy. New York: Academic Press, 1991:223-53.
4. Clarke R, Lippman ME, Dickson RB. Mechanism of hormone and cytotoxic drug interactions in the development and treatment of breast cancer. Prog Clin Biol Res 1989;322:243-78.
5. Morrow CS, Chiu J, Cowan KH. Posttranscriptional control of glutathione S-transferase pi gene expression in human breast cancer cells. J Biol Chem 1992;267:10544-50.
6. Molina R, Oesterreich S, Zhou JL, Tandon AK, Clark GM, Allred DC, et al. Glutathione transferase GST pi in breast tumors evaluated by three techniques. Dis Markers 1993;11:71-82.
7. Zyad A, Benard J, Tursz T, Clarke R, Chouaib S. Resistance to TNF-α and adriamycin in the human breast cancer MCF-7 cell line: relationship to MDR1, MnSOD, and TNF gene expression. Cancer Res 1994;54:825-31.
8. Tuccari G, Rizzo A, Giuffre G, Barresi G. Immunocytochemical detection of DNA topoisomerase type II in primary breast carcinomas: correlation with clinico-pathological features. Virchows Arch A Pathol Anat Histopathol 1993;423:51-5.
9. Schneider E, Horton JK, Yang CH, Nakagawa M, Cowan KH. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res 1994;54:152-8.
10. Vickers PJ, Dickson RB, Shoemaker R, Cowan KH. A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo. Mol Endocrinol 1988;2:886-92.
11. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455: 152-62.
12. Ambudkar SV, Lelong IH, Zhang J, Cardarelli CO, Gottesman MM, Pastan I. Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis. Proc Natl Acad Sci U S A 1992;89:8472-6.
13. Bruggemann EP, Currier SJ, Gottesman MM, Pastan I. Characterization of the azidopine and vinblastine binding site of P-glycoprotein. J Biol Chem 1992;267:21020-6.
14. Raviv Y, Pollard HB, Bruggemann EP, Pastan I, Gottesman MM. Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J Biol Chem 1990;265:3975-80.
15. Hamada H, Hagiwara K, Nakajima T, Tsuruo T. Phosphorylation of the Mr 170,000 to 180,000 glycoprotein specific to multidrug-resistant tumor cells: effects of verapamil, trifluoperazine and phorbol esters. Cancer Res 1987;47:2860-5.
16. Chambers TC, Zheng B, Kuo JF. Regulation by phorbol ester and protein kinase C inhibitors, and by a protein phosphatase inhibitor (okadaic acid), of P-glycoprotein phosphorylation and relationship to drug accumulation in multidrug-resistant human KB cells. Mol Pharmacol 1992;41: 1008-15.
17. Yu G, Ahmad S, Aquino A, Fairchild CR, Trepel JB, Ohno S, et al. Transfection with protein kinase C alpha confers increased multidrug resistance to MCF-7 cells expressing P-glycoprotein. Cancer Commun 1991;3:181-9.
18. Escriba PV, Ferrer-Montiel AV, Ferragut JA, Gonzalez-Ros JM. Role of membrane lipids in the interaction of daunomycin with plasma membranes from tumor cells: implications in drug-resistance phenomena. Biochemistry 1990;29:7275-82.
19. Clarke R, van den Berg HW, Murphy RF. Reduction of the membrane fluidity of human breast cancer cells by tamoxifen and 17β-estradiol. J Natl Cancer Inst 1990;82:1702-5.
20. Sinicrope FA, Dudeja PK, Bissonnette BM, Safa AR, Brasitus TA. Modulation of P-glycoprotein-mediated drug transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles. J Biol Chem 1992; 267:24995-5002.
21. Woodcock DM, Linsenmeyer ME, Chojnowski G, Kriegler AB, Nink V, Webster LK, et al. Reversal of multidrug resistance by surfactants. Br J Cancer 1992;66:62-8.
22. Gottesman MM. How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1993;53: 747-54.
23. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991;83:1797-805.
24. Fisherman JS, Cowan KH, Noone M, Denicoff A, Berg S, Poplack D, et al. Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer. J Clin Oncol 1996;14:774-82.
25. Sanfilippo O, Ronchi E, De Marco C, Di Fronzo G, Silvestrini R. Expression of P-glycoprotein in breast cancer tissue and in vitro resistance to doxorubicin and vincristine. Eur J Cancer 1991;27:155-8.
26. Salmon SE, Grogan TM, Miller T, Scheper R, Dalton WS. Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. J Natl Cancer Inst 1989;81:696-701.
27. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai S, Gazdar A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989;81:116-24.
28. Merkel DE, Fuqua SA, Tandon AK, Hill SM, Buzdar AU, McGuire WL. Electrophoretic analysis of 248 clinical breast cancer specimens for P-glycoprotein overexpression or gene amplification. J Clin Oncol 1989;7: 1129-36.
29. Moscow JA, Fairchild CR, Madden MJ, Ransom DT, Wieand HS, O'Brien EE, et al. Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res 1989;49:1422-8.
30. Ronchi E, Sanfilippo O, Di Fronzo G, Bani MR, Della Torre G, Catania S, et al. Detection of the 170 kDa P-glycoprotein in neoplastic and normal tissues. Tumori 1989;75:542-6.
31. Shapiro S. Meta-analysis/Shmeta-analysis. Am J Epidemiol 1994;140: 771-8.
32. Petitti DB. Of babies and bathwater. Am J Epidemiol 1994;140:779-82.
33. Greenland S. Invited commentary: a critical look at some popular meta-analytic methods. Am J Epidemiol 1994;140:290-6.
34. Greenland S. Can meta-analysis be salvaged? Am J Epidemiol 1994;140: 783-7.
35. Mulrow CD. The medical review article: state of the science. Ann Intern Med 1987;106:485-8.
36. Oxman AD, Guyatt GH. Guidelines for reading literature reviews. Can Med Assoc J 1988;183:697-703.
37. Milne R, Chambers L. Assessing the scientific quality of review articles. J Epidemiol Community Health 1993;47:169-70.
38. Leonessa F, Jacobson M, Boyle B, Lippman J, McGarvey M, Clarke R. Effect of tamoxifen on the multidrug-resistant phenotype in human breast cancer cells: isobologram, drug accumulation, M(r) 170,000 glycoprotein (gp170) binding studies. Cancer Res 1994;54:441-7.
39. Ramu A, Glaubiger D, Fuks Z. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues. Cancer Res 1984;44:4392-5.
40. Dickersin K, Berlin JA. Meta-analysis: state-of-the-science. Epidemiol Rev 1992;14:154-76.
41. Chalmers TC. Problems induced by meta-analyses. Stat Med 1991;10: 971-80.
42. Gerbarg ZB, Horwitz RI. Resolving conflicting clinical trials: guidelines for meta-analysis. J Clin Epidemiol 1988;41:503-9.
43. Weed DL. Methodologie guidelines for review papers [editorial]. J Natl Cancer Inst 1997;89:6-7.
44. Theillet C, Le Roy X, De Lapeyriere O, Grosgeorges J, Adnane J, Raynaud SD, et al. Amplification of FGF-related genes in human tumors: possible involvement of HST in breast carcinomas [published erratum appears in Oncogene 1989;4:1537]. Oncogene 1989;4:915-22.
45. Smith K, Houlbrook S, Greenall M, Carmichael J, Harris AL. Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene 1993;8:933-8.
46. Kim R. Expression of the multidrug resistance gene in human tumors. Hiroshima J Med Sci 1990;39:71-7.
47. Chevillard S, Pouillart P, Beldjord C, Asselain B, Beuzeboc P, Magdelenat H, et al. Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer 1996;77:292-300.
48. Fleiss JL. Statistical methods for rates and proportions. New York: John Wiley & Sons, 1981:33-46.
49. Snedecor GW, Cochran WG. Statistical methods. Ames (IA): Iowa State University Press, 1976:213-53.
50. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987;9:1-30.
51. Breslow NE, Day NE. Statistical methods in cancer research. Volume II - the design and analysis of cohort studies. Lyon: IARC, 1987:109-12.
52. Landis RJ, Heyman ER, Koch GG. Average partial association in three-way contingency tables: a review and discussion of alternative tests. Int Stat Rev 1978;46:237-54.
53. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research. New York: Van Nostrand Reinhold Co., 1982:143-7.
54. Kacinski BM, Yee LD, Carter D, Li D, Kuo MT. Human breast carcinoma cell levels of MDR-1 (P-glycoprotein) transcripts correlate in vivo inversely and reciprocally with tumor progesterone receptor content. Cancer Commun 1989;1:1-6.
55. Schneider J, Bak M, Efferth T, Kaufmann M, Mattern J, Volm M. P-glycoprotein expression in treated and untreated human breast cancer. Br J Cancer 1989;60:815-8.
56. Keith WN, Stallard S, Brown R. Expression of mdr1 and gst-π in human breast tumours: comparison to in vitro chemosensitivity. Br J Cancer 1990;61:712-6.
57. Ro J, Sahin A, Ro JY, Fritsche H, Hortobagyi G, Blick M. Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Pathol 1990; 21:787-91.
58. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990;38: 1277-87.
59. Sugawara I. Expression and functions of P-glycoproiein (mdr1 gene product) in normal and malignant tissues. Acta Pathol Jpn 1990;40:545-53.
60. Wallner J, Depisch D, Hopfner M, Haider K, Spona J, Ludwig H, et al. MDR1 gene expression and prognostic factors in primary breast carcinomas. Eur J Cancer 1991;27:1352-5.
61. Verrelle P, Meissonnier F, Fonck Y, Feillel V, Dionet C, Kwiatkowski F, et al. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 1991; 83:111-6.
62. Koh EH, Chung HC, Lee KB, Lim HY, Kim JH, Roh JK, et al. The value of immunohistochemical detection of P-glycoprotein in breast cancer before and after induction chemotherapy. Yonsei Med J 1992;33:137-42.
63. Hennequin E, Delvincourt C, Pourny C, Jardillier JC. Expression of mdr1 gene in human breast primary tumors and metastases. Breast Cancer Res Treat 1993;26:267-74.
64. Veneroni S, Zaffaroni N, Daidone MG, Benini E, Villa R, Silvestrini R. Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers. Eur J Cancer 1994; 30A:1002-7.
65. Charpin C, Vielh P, Duffaud F, Devictor B, Andrac L, Lavaut MN, et al. Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: correlation to messenger RNA expression and to immunohistochemical prognostic indicators. J Natl Cancer Inst 1994;86: 1539-45.
66. Wishart GC, Plumb JA, Going JJ, McNicol AM, McArdle CS, Tsuruo T, et al. P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies. Br J Cancer 1990: 62:758-61.
67. Keen JC, Miller EP, Bellamy C, Dixon JM, Miller WR. P-glycoprotein and resistance to tamoxiten [letter]. Lancet 1994;343:1047-8.
68. Dixon AR, Bell J, Ellis IO, Eiston CW, Blamey RW. P-glycoprotein expression in locally advanced breast cancer treated by neoadjuvant chemotherapy. Br J Cancer 1992;66:537-41.
69. Botti G, Chiappetta G, D'Aiuto G, de Angelis E, De Matteis A, Montella M, et al. PCNA/cyclin and P-glycoprotein as prognostic factors in locally advanced breast cancer. An immunohistochemical, retrospective study. Tumori 1993;79:214-8.
70. Schneider J, Rubio MP, Barbazan MJ, Rodriguez-Escudero FJ, Seizinger BR, Castresana JS. P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors. J Natl Cancer Inst 1994;86:850-5.
71. Linn SC, Giaccone G, van Diest PJ, Blokhuis WM, van der Valk P, van Kalken CK, et al. Prognostic relevance of P-glycoprotein expression in breast cancer. Ann Oncol 1995;6:679-85.
72. Luowen H, Chunyi H, Benyao L, Yi W, Fei G. P-glycoprotein expression in primary breast cancer. Chin Med Sci J 1995;12:12-5.
73. Seymour L, Bezwoda WR, Dansey RD. P-glycoprotein immunostaining correlates with ER and with high Ki67 expression but fails to predict anthracycline resistance in patients with advanced breast cancer. Breast Cancer Res Treat 1995;36:61-9.
74. Decker DA, Morris LW, Levine AJ, Pettinga JE, Grudzien JL, Farkas DH. Immunohistochemical analysis of P-glycoprotein expression in breast cancer: clinical correlations. Ann Clin Lab Sci 1995;25:52-9.
75. Schneider J, Romero H. Correlation of P-glycoprotein overexpression and cellular prognostic factors in formalin-fixed, paraffin-embedded tumor samples from breast cancer patients. Anticancer Res 1995;15: 1117-21.
76. O'Driscoll L, Kennedy S. McDermott E, Kelehan P, Clynes M. Multiple drug resistance-related messenger RNA expression in archival formalin-fixed paraffin-embedded human breast tumour tissue. Eur J Cancer 1996; 32A:128-33.
77. Lonn U, Lonn S, Nylen U, Stenkvist B. Appearance and detection of multiple copies of the mdr-1 gene in clinical samples of mammary carcinoma. Int J Cancer 1992;51:682-6.
78. Kim R, Hirabayashi N, Nishiyama M, Saeki S, Toge T, Okada K. Expression of MDR1, GST-π and topoisomerase II as an indicator of clinical response to adriamycin. Anticancer Res 1991;11:429-31.
79. Scala S, Saeki T, Lynch A, Salomon DS, Merino MJ, Bates SE. Coexpression of TGF α, epidermal growth factor receptor, and P-glycoprotein in normal and benign breast tissues. Diagn Mol Pathol 1995;4: 136-42.
80. Sugawara I, Kataoka I, Morishita Y, Hamada H, Tsuruo T, Itoyama S, et al. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res 1988; 48:1926-9.
81. van der Heyden S, Gheuens E, DeBruijn E, Van Oosterom A, Maes R. P-glycoprotein: clinical significance and methods of analysis. Crit Rev Clin Lab Sci 1995;32:221-64.
82. Bittl A, Nap M, Jager W, Lathan B, Lang N. Immunohistochemical detection of P-glycoprotein in normal and malignant tissues: a comparative study of three monoclonal antibodies, JSB-1, C 219 and 265/F4, against different epitopes using frozen and paraffin tissue sections. Tumour Biol 1993;14:155-66.
83. Georges E, Bradley G, Gariepy J, Ling V. Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies. Proc Natl Acad Sci U S A 1990;87:152-6.
84. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem 1989;37:159-64.
85. Rao VV, Anthony DC, Piwnica-Worms D. Multidrug resistance P-glycoprotein monoclonal antibody JSB-1 crossreacts with pyruvate carboxylase. J Histochem Cytochem 1995;43:1187-92.
86. Rao VV, Anthony DC, Piwnica-Worms D. MDR1 gene-specific monoclonal antibody C494 cross-reacts with pyruvate carboxylase. Cancer Res 1994;54:1536-41.
87. Schinkel AH, Roelofs EM, Borst P. Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies. Cancer Res 1991;51:2628-35.
88. Clarke R, Dickson RB, Lippman ME. Hormonal aspects of breast cancer. Growth factors, drugs and stromal interactions. Crit Rev Oncol Hematol 1992;12:1-23.
89. Kaye SB. P-glycoprotein (P-gp) and drug resistance - time for reap-praisal? Br J Cancer 1993;67:641-3.
90. Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutherford AV, Willingham MC. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci U S A 1988;85:4486-90.
91. Clarke R, Currier S, Kaplan O, Lovelace E, Boulay V, Gottesman MM, et al. Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells. J Natl Cancer Inst 1992;84: 1506-12.
92. Leonessa F, Green D, Licht T, Wright A, Wingate-Legette K, Lippman J, et al. MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer. Br J Cancer 1996;73:154-61.
93. Light RJ, Pillemer DB. Summing up: the science of reviewing research. Cambridge (MA): Harvard University Press, 1984.
94. Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 1996;56:3010-20.
95. Hamblin TJ. 1st international conference on reversal of multidrug resistance in cancer. Leuk Res 1995;19:427-8.
96. Broxterman HJ, Lankelma J, Pinedo HM. How to probe clinical tumour samples for P-glycoprotein and multidrug resistance-associated protein. Eur J Cancer 1996;32A:1024-33.
97. Fuqua SA, Fitzgerald SD, McGuire WL. A simple polymerase chain reaction method for detecting and cloning of low-abundance transcripts. Biotechniques 1990;9:206-11.
98. Grogan T, Dalton W, Rybski J, Spier C, Meltzer P, Richter L, et al. Optimization of immunocytochemical P-glycoprotein assessment in multidrug-resistant plasma cell myeloma using three antibodies. Lab Invest 1990;63:815-24.
99. Kamby C, Andersen J, Ejlertsen B, Birkler NE, Rytter L, Zedeler K, et al. Histological grade and steroid receptor content of primary breast cancer -impact on prognosis and possible modes of action. Br J Cancer 1988;58: 480-6.
100. Andersen J, Thorpe SM, King WJ, Rose C, Christensen I, Rasmussen BB, et al. The prognostic value of immunohistochemical estrogen receptor analysis in paraffin-embedded and frozen sections versus that of steroid-binding assay. Eur J Cancer 1990;26:442-9.
101. Foekens JA, Portengen H, van Putten WL, Peters HA, Krijnen HL, Alexieva-Figusch J, et al. Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res 1989;49:5823-8.
102. De Potter CR, Schelfhout AM. The neu-protein and breast cancer. Virchows Arch 1995;426:107-15.
103. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer [published erratum appears in N Engl J Med 1994; 331:211]. N Engl J Med 1994;330:1260-6.
104. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
105. Elledge RM, Fuqua SA, Clark GM, Pujol P, Allred DC. William L. McGuire Memorial Symposium. The role and prognostic significance of p53 gene alterations in breast cancer. Breast Cancer Res Treat 1993;27: 95-102.
106. Pavelic ZP, Reising J, Pavelic L, Kelley DJ, Stambrook PJ, Gluckman JL. Detection of p-glycoprotein with four monoclonal antibodies in normal and tumor tissues. Arch Otolaryngol Head Neck Surg 1993;119:753-7.
107. Paterson AH, Cyr M, Szafran O, Lees AW, Hanson J. Response to treatment and its influence on survival in metastatic breast cancer. Am J Clin Oncol 1985;8:283-92.
108. Cheblowski RT, Irwin LE, Pugh RP, Sadoff L, Hesteroff R, Wiener JM, et al. Survival of patients with metastatic breast cancer treated with either combination chemotherapy or sequential chemotherapy. Cancer Res 1979; 39:4503-6.
109. De La Torre M, Larsson R, Nygren P, Lindgren A, Bergh J. Expression of the multidrug-resistance gene product in untreated human breast cancer and its relationship to prognostic markers. Acta Oncol 1994;33: 773-7.
110. Herzog CE, Tsokos M, Bates SE, Fojo AT. Increased mdr-1/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists. J Biol Chem 1993;268:2946-52.
111. Batist G, Tulple A, Sinha BK, Katki AG, Myers CE, Cowan KH. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 1986;261:15544-9.
112. Sinha BK, Mimnaugh EG, Rajagopalan S, Myers CE. Adriamycin activation and oxygen free radical formation in human breast tumor cells: protective role of glutathione peroxidase in adriamycin resistance. Cancer Res 1989;49:3844-8.
113. Fuqua SA, Oesterreich S, Hilsenbeck SG, Von Hoff DD, Eckardt J, Osborne CK. Heat shock proteins and drug resistance. Breast Cancer Res Treat 1994;32:67-71.
114. Schuurhuis GJ, Broxterman HJ, Ossenkopple GJ, Baak JP, Eekman CA, Kuiper CM, et al. Functional multidrug resistance phenotype associated with combined overexpression of pgp/MDR1 and MRP together with 1-β-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia. Clin Cancer Res 1995;1:81-93.
115. Demicheli R, Jirillo A, Bonciarelli G, Lonardi F, Balli M, Bandello A. 4'Epidoxorubicin plus verapamil in anthracycline-refractory cancer patients. Tumori 1989;75:245-7.
116. Wishart GC, Bissett D, Paul J, Jodrell D, Harnett A, Habeshaw T, et al. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. J Clin Oncol 1994;12:1771-7.
117. Mross K, Bohn C, Edler L, Jonat W, Queisser W, Heidemann E, et al. Randomized phase II study of single-agent epirubicin +/-verapamil in patients with advanced metastatic breast cancer. An AIO clinical trial. Arbeitsgemeinschaft Internistische Onkologie of the German Cancer Society. Ann Oncol 1993;4:45-50.
118. Miller RL, Bukowski RM, Budd GT, Purvis J, Weick JK, Shepard K, et al. Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: a phase I/II trial. J Clin Oncol 1988;6: 880-8.
119. Mross K. Multidrug-resistance modulation in metastatic breast cancer patients [letter]. J Clin Oncol 1996;13:303-4.
120. Staging for carcinoma of the breast. In: Beahrs O, Henson D, Hutter R, Myers M, editors. Manual for staging of cancer. 3rd ed. Philadelphia: Lippincott, 1988:145-50.
121. Bloom HJ, Richardson WW. Histologic grading and prognosis in breast cancer. Br J Cancer 1957;11:359-77.